A total of 24 male and female donkeys of local breed, 4-10 years of age and naturally infected with helminth parasites was utilized in a controlled study to evaluate the efficacy of Moxidectin injectable formulation at the dosage of 0.2 mg/kg of live weight used either subcutaneously or intramuscularly and an ivermectin injectable formulation at the dosage of 0.2 mg per Kg applied subcutaneously. Animals were allocated randomly into four groups of six donkeys each, and treatments were randomized among the groups. One group was kept as untreated control. Theexperiment extended for 14 days. Faecal samples were collected at day 0 (before treatment), and then at 1, 2, 3, 7 and 14 days post treatment. The number of parasites remaining in each animal was determined after necropsy of the animals at day 14 post treatment for all donkeys. Both Moxidectin subcutaneously or intramuscularly and ivermectin administered subcutaneously reduced initial EPG from a mean of 550, 700, and 600 to 50 (90.9%), 150 (78.5%), and zero (100%) at the end of trial on day 14. Efficacy percentages of Moxidectin and ivermectin against immature and adult nematodes were as follows: Trichostrongylus axei, Parascaris equorum. Habronema muscae 100% for both products; respectively. Cyathostomes spp.; Strongyloides westeri and Oxyuris equi 100%,for the two products. No Gasterophilus larvae were found in donkeys from treated groups, while all the control donkeys had infections with this parasite. Ivermectin showed greater efficacy (99.8%) than moxidectin (74.4 and 98%) against Strongylus vulgaris larvae found in the mesenteric artery aneurisms. No adverse reactions were observed during the experimental period.